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ABSTRACT 
 
Most non-small cell lung cancers (NSCLCs) contain non-targetable mutations, including KRAS, 
TP53 or STK11/LKB1 alterations. By coupling ex vivo drug sensitivity profiling with in vivo drug 
response studies, we aimed to identify drug vulnerabilities for these NSCLC subtypes. Primary 
adenosquamous carcinoma (ASC) or adenocarcinoma (AC) cultures were established from 
Kras
G12D
;Lkb1 
fl/fl
 (KL) tumors or AC cultures from Kras
G12D
;p53
fl/fl
 (KP) tumors. While p53 null 
cells readily propagated as conventional cultures, Lkb1 null cells required conditional 
reprograming for establishment. Drug response profiling revealed short-term response to MEK 
inhibition, yet, long-term clonogenic assays demonstrated resistance, associated with sustained or 
adaptive activation of receptor tyrosine kinases (RTKs): activation of ERBBs in KL cultures, or 
FGFR in AC cultures. Furthermore, pan-ERBB inhibition reduced the clonogenicity of KL 
cultures, which was exacerbated by combinatorial MEK inhibition, while combinatorial MEK and 
FGFR inhibition suppressed clonogenicity of AC cultures. Importantly, in vivo studies confirmed 
KL-selective sensitivity to pan-ERBB inhibition, which correlated with high ERBB ligand 
expression and activation of ERBB receptors, implying that ERBB network activity may serve as 
a predictive biomarker of drug response. Interestingly, in human NSCLCs, phosphorylation of 
EGFR or ERBB3 was frequently detected in ASCs and squamous cell carcinomas. We conclude 
that analysis of in situ ERBB signaling networks in conjunction with ex vivo drug response 
profiling and biochemical dissection of adaptive RTK activities may serve as valid diagnostic 
approach to identify tumors sensitive to ERBB network inhibition. 
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INTRODUCTION 
NSCLC is a genetically and histologically complex disease. Genetic analyses have revealed 
recurrent alterations, with approximately 60% of ACs and 50-80% of SCCs carrying histotype-
selective alterations (1). ALK rearrangements and mutations in EGFR and KRAS are predominant 
in ACs, while loss of function mutations in TP53 and PTEN, as well as amplification of FGFR1 
and SOX2, are common to SCC (2). The combination of KRAS mutation with loss of function 
mutation in LKB1 (also called STK11) is detected in 30% of NSCLC tumors, and this represents 
an aggressive subset with poor prognosis (3). Despite clinical advances with targeted therapies 
against mutant EGFR or ALK, long-term patient survival is compromised due to acquired drug 
resistance (4,5). Furthermore, treatment vulnerabilities and resistance mechanisms that arise in 
histopathology-specific contexts in the absence of targetable drivers, such as NSCLC driven by 
Kras
G12D
 and Lkb1 loss, remain largely unexplored. 
 
Using a genetically engineered mouse model (GEMM) harboring Kras
G12D
 activation together 
with Lkb1 loss (KL), we previously showed that NSCLC histotype diversity is dependent on the 
tumor cell of origin. The most aggressive clinical histopathology subtype, ASC, which consists of 
a mixture of SCC and AC, is predominantly derived from CC10
+
 (Club cell antigen 10) 
progenitors (6,7). On the other hand, mice harboring conditional expression of Kras
G12D 
with 
concomitant loss of p53 exclusively produce AC tumors, irrespective of the progenitor cell (8). 
The KP and KL GEMMs also demonstrate differences in tumor latency and metastatic propensity, 
as well as therapeutic sensitivity (9,10). Importantly, using these GEMMs, we recently showed 
that signaling variance does not merely associate with oncogenetic background, but stratifies 
mostly according to tumor histopathology, with predominant AKT and SRC activity detected in 
ASCs and MAPK activity in ACs (11). We further found that NSCLC histotype associates with 
immune gene signatures and immune cell infiltrations (7). Since both tumor histotype and 
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genotype thus appear to dictate oncogenic phenotypes, deeper analysis of NSCLC histopathology-
selective drug sensitivities is warranted.  
 
While ex vivo drug profiling of patient-derived fresh leukemic cells has been successfully adopted 
(12), an outstanding question remains how similar strategy could be applied to solid tumors. 
Patient-derived xenograft and organoid models have been extensively used for this purpose 
(13,14). However, these models undergo molecular divergence with increased passaging, poorly 
represent the tumor microenvironment, and are time consuming. While in vitro cultures from PDX 
models can readily be established likely due to adaptation following passaging in mice, generation 
of primary cultures from freshly resected tumors is challenging. A recent advancement in cell 
culture methodology permits indefinite culture of primary epithelial cells from mouse models and 
clinical biopsies, (15-18). This method involves conditional reprogramming (CR) of primary cells 
by co-culturing with irradiated 3T3 feeder cells in media containing a Rho kinase inhibitor (19). 
CR cultures have been shown to retain the genetic profiles of source tumors, including intra-tumor 
genetic heterogeneity (20,21). However, thus far the CR technology has not been applied to 
assessment of lesion-specific drug sensitivity mechanisms in GEMMs, and an open question 
remains how in vitro drug responses recapitulate mechanisms active in vivo. We here employed 
the CR technology to establish primary cultures from KP and KL tumors representing different 
histopathologies, and show that the combination of ex vivo and in vivo drug response profiling 
exposes NSCLC histopathology subtype-selective signaling plasticities and associated therapeutic 
vulnerabilities. 
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MATERIALS AND METHODS 
 
Animal experiments 
Animal experiments were conducted following the guidelines from the Finnish National Board of 
Animal Experimentation (permit number ESAVI/9752/04.10.07/2015). Mouse breeding and 
Adenoviral Cre (AdCre) infections were performed as described previously (7).  
 
Tissue dissociation and isolation of epithelial cells 
Lung tumors were minced into smaller pieces, followed by enzymatic digestion with collagenase 
and dispase, and the resulting mixture was mechanically dissociated using a gentleMACS
TM  
 
dissociator. Epithelial cells were isolated using EpCAM MicroBeads (MACS Miltenyi biotec; 
130-105-958). A more detailed description is in the Supplementary Methods. 
 
Cell culture 
Epithelial cells were either cultured on plastic with RPMI containing 10% FBS, 10 mM glutamine, 
50 U/mL penicillin, and 50 g/mL streptomycin (Thermo Fisher Scientific), or CRCs, as 
described (19). In brief, cells were plated on irradiated 3T3 feeder cells in F-medium containing 
10 M Rho kinase inhibitor Y-27632 (CRC medium). CR cultures were differentially trypsinized, 
first to remove the feeder cells, followed by trypsinization of the epithelial cells. More details are 
provided in the Supplementary Methods.   
 
Colony formation assays 
KL, KP, or NL CRCs at passage 7 were plated at 500 cells per well in 6-well plates, and cultivated 
in CRC medium or in F-medium without Y-27632. To evaluate drug treatment effects, compounds 
or vehicle were added 48 h following cell seeding. At day 11 for routine assays, or day 13 for drug 
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treatment assays, colonies were fixed using a mixture of acetic acid and methanol (1:7 vol/vol), 
and stained with 0.5% crystal violet in methanol. Colonies were counted manually, and the colony 
formation rate was calculated as the percentage of cells that formed colonies per 500 cells. 
Colonies from the drug treatment studies were analyzed to determine the percentage of area 
covered by colonies using the ‘ColonyArea’ Image J plugin (22), and normalized to DMSO 
controls.  
 
Immunoblotting 
Protein lysates from source tumor references or CRC pellets were prepared using RIPA buffer. 
Protein concentrations were measured using BCA analysis (G Biosciences; 786-570). Protein 
samples (20 g) were analyzed by western blotting. Membranes were blocked using the 
Odyssey® Blocking Buffer (927-40000), and odyssey IRDye secondary antibodies were used. 
Membranes were analyzed using an odyssey infrared imager.  
 
Drug Sensitivity and Resistance Testing (DSRT) 
 
Murine NL and tumor CRCs at passage 4 were used for DSRT following published procedures 
(12), with minor modifications. A library of 299 oncology compounds listed in Table S1 was used 
in this study. Drugs were dispensed into clear bottom 384-well plates (Corning #3712) using an 
Echo 550 Liquid Handler (Labcyte), at five concentrations covering a 10,000-fold concentration 
range. As negative and positive controls, 0.1% dimethyl sulfoxide (DMSO) and 100 μM 
benzethonium chloride were included in wells scattered across the plates. Pre-drugged DSRT 
plates were stored in pressurized Storage Pods (Roylan Developments Ltd.) and used within one 
month. Cells (1500 per well) were seeded in DSRT plates using a MultiDrop Combi dispenser 
(Thermo Fisher Scientific), in 25 l F-medium with or without Y-27632. Following 72 h 
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cultivation at 37C, 25 l CellTiter-Glo® reagent (Promega) was added in each well, and cell 
viability was measured using a PheraStar plate reader (BMG Labtech). 
Cell viability analysis  
Tumor- and normal lung-derived CRCs were seeded in 384-well plates (1500 cells per well). 
Following 24 h cultivation, cells were treated with indicated drugs or DMSO for 72 h. Cell 
viability was determined by CellTiter-Glo
®
 (Promega), as described above.  
 
In vivo combination treatment with trametinib and afatinib 
Age- and sex-matched KL or KP mice infected with Ad5-CC10-Cre or Ad5-SPC-Cre viruses at 7-
9 or 15 weeks post infection (wpi) were randomly assigned into treatment groups. Mice were 
either treated with vehicle, with 1 mg/kg trametinib in 0.9 % saline intraperitoneally (IP), or with 
12.5 mg/kg afatinib in 0.5% hydroxyl propyl methyl cellulose (HPMC) and 0.1% Tween 80 in 
H2O by oral gavage. For combination treatments, 1 mg/kg trametinib and 12.5 mg/kg afatinib was 
administered IP and by oral gavage, respectively. Mice were treated for four weeks, three times 
per week on Monday, Wednesday, and Friday, and sacrificed by cervical dislocation.  
 
Tissue preparation, immunohistochemistry (IHC), and tumor burden analysis 
Tissue processing, IHC, and image quantifications were performed as described previously (7), 
and all IHC samples within an experimental group were processed using comparable experimental 
conditions. Tumor burden analysis was performed on H&E stained tissue sections using ImageJ.  
 
Human lung cancer tissue microarray (TMA) analyses 
Human NSCLC TMAs were prepared as described previously (7). Briefly, ASC (n=13), AC 
(n=25), and SCC (n=28) tumor samples operated during 2000-2015 at the Hospital District of 
Helsinki and Uusimaa (HUS) Finland were used for TMA preparation, under approval by the 
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ethics committee of the Joint Authority for HUS (Dnro: 85/13/03/00/15). Two-three replicate 
cores of 2 mm diameter were included in the analyses. 
 
Real-time quantitative PCR (RT-qPCR) 
Total RNA from snap frozen tumor or normal lung tissue samples was extracted using the 
NucleoSpin RNA II kit (MACHEREY-NAGEL, Duren, Germany). Complementary DNA 
(cDNA) was synthesized using a high-capacity cDNA reverse transcription kit (Lifetechnologies, 
Waltham, USA). qPCR was performed using iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, 
USA) and were run on a CFX384 Touch
TM
 Real-Time PCR Detection System (Bio-Rad, Hercules, 
USA). Gene expression ratios were determined using the Paffl method (23), normalized to the 
Actb housekeeping gene. Primer details are provided in Supplementary Table 2. 
 
Statistical analysis 
For statistical analysis, a Student’s t test, nonparametric Kolmogorov-Smirnov test, or a Fisher’s 
test (human NSCLC TMA analyses) were used. Error bars indicate standard deviation or standard 
error of the mean. The results were considered statistically significant if a p-value <0.05 was 
observed. Pearson’s correlation coefficients were used to compare drug sensitivities in the 
presence or absence of ROCK inhibitor.  
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RESULTS 
 
 
CR cultures of different NSCLC subtypes represent growth properties of native tumors 
To identify NSCLC lesion-specific therapeutic vulnerabilities, we set out to derive primary 
cultures from murine tumors representing different histopathologies and genotypes, as well as 
normal lung (NL) epithelia. Cell cultures derived from KL;ASCs (n=4), KL;ACs (n=3), and 
KP;ACs (n=4) were established as conditionally reprogrammed cultures (CRCs), or as traditional 
RPMI cultures. The source tumor histopathologies were confirmed by NKX2-1 and p63 lineage 
marker staining (Fig. S1A). KP tumor-derived cells readily established in RPMI medium, without 
the support of feeder cells or Y-27632. In contrast, most KL tumor-derived cells did not survive 
beyond the first passage when grown in RPMI, yet readily established as CR cultures (Fig. 1A and 
S1B). Hence, KL tumor-derived cells of both AC and ASC histotypes required cultivation as 
CRCs for long-term survival, and NSCLC culture genotype (KP, but not KL) was the main 
determinant governing the ability of cells to establish as conventional RPMI cultures. 
 
Following the establishment phase, both tumor and normal lung CRCs could readily be passaged 
as logarithmically-growing cultures. Cultured cells lacked LKB1 or p53 protein expression and 
maintained E-cadherin expression, confirming their genotype and epithelial identity, respectively 
(Fig. 1B-1C and S1C-1D). Expression of vimentin, a mesenchymal marker, was detected 
predominantly in KP cells (Fig. 1C and S1C-1D). KL;ASC #2, a culture established without 
EpCAM epithelial cell purification, contained stromal cells marked by vimentin and LKB1 protein 
expression (Fig. 1B and S1C-1D), indicating that EpCAM purification was essential to derive pure 
epithelial cultures. Interestingly, KL;ASC cultures grew faster than KL;AC cultures (Fig. S1E), 
which is consistent with the finding that in vivo KL;ASC lesions contain more Ki67-expressing 
proliferating cells and are larger than KL;AC tumors (7,11). Clonogenicity assays similarly 
showed that the clonogenic potential of KL;ASC cells was higher than that of KL;AC cells, and 
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that KL cultures depended on inclusion of Y-27632 for survival (Fig. 1D-E). In contrast, the 
clonogenicity of KP;AC cultures was negatively affected by Y-27632 (Fig. 1D-E), demonstrating 
genotype-selective differences in growth properties. We conclude that primary cultures represent 
the genetic identity of their source tumors, and that NSCLC subtype-specific tumorigenicity 
differences are detected also in vitro.  
 
Next, we asked whether cultures retained NSCLC histotype-specific lineage marker expression in 
vitro. We assessed expression of the transcription factors NKX2-1 (marking AC and ASC 
pathologies) and p63 (marking ASC pathology) in two- or three-dimensional cultures, and 
compared these with source tumors. Expression of p63, specific for KL;ASCs, was retained in 
vitro (Fig. S1F-1G). On the other hand, NKX2-1 expression was decreased in KL;ASC cultures or 
lost in KP;AC and KL;AC cultures, and this was not rescued by cultivation in three dimensions 
(Fig. S1F and S1H). This tentatively indicates that squamous, but not adenocarcinoma, histotype 
differentiation was retained in CR cultures.  
 
Drug sensitivity and resistance testing (DSRT) identifies histotype- and driver genotype-
selective therapeutic vulnerabilities 
We hypothesized that genotype- and histotype-related heterogeneity in Kras mutant NSCLC 
determines differential responses to drug perturbation. Before implementing drug screens, we first 
assessed the ability of cultures to model known drug responses, and measured the effect of 
idasanutlin, an inhibitor of Mdm2-p53 interaction and activator of p53. Drug responses were 
determined as Drug Sensitivity Scores (DSSs) (12), which integrates calculation of the area under 
the dose response curve (AUC) in conjunction with parameters including IC50, slope, and top and 
lower asymptotes. As expected, p53-expressing KL cultures of both histopathologies showed 
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significantly higher idasanutlin response compared with KP;AC cultures (Fig. S2A), providing 
confidence on the validity of the taken approach. 
 
Next, we conducted DSRT studies on these murine cultures representing different genotypes (KP 
or KL) and histotypes (AC or ASC) (Fig. 2A). Cancer cell-selective drug sensitivities were 
calculated by subtracting the DSS of individual tumor cultures from average DSS scores 
determined in NL cultures (n=3) for each drug, determining selective drug sensitivity scores 
(sDSS) (12,24). A sDSS greater than 5 or less than -5 was considered as a hit for sensitivity or 
resistance, respectively. We first performed replicate screens with 299 compounds on the four 
culture types, either in the presence or absence of Y-27632. Comparison of the DSS data indicated 
a significant correlation (R
2
 ≥ 0.85, p < 0.0001) between screens conducted with or without Y-
27632; on the contrary, correlation tests between any other two cell lines showed a lesser degree 
of correlation (R
2
 ≤ 0.85), indicating that Y-27632 does not overtly affect drug response (Fig. 
S2B-C). Since CR culture requires addition of Y-27632 for long-term propagation, subsequent 
studies therefore included Y-27632. To further validate the screen results, 61 compounds 
exhibiting sDSS ≥ 5 and ≤ -5 for at least one of the tumor cultures were evaluated in a second 
phase screen, using multiple biological replicates per culture subtype (Fig. 2A). Data from these 
screens were combined to identify culture subtype-selective drug sensitivity profiles. This showed 
that KL;ASC cultures were more sensitive to drug treatment, exhibiting sensitivity to 19 
compounds, while KP;AC and KL;AC cultures were more resistant, showing sensitivity to one or 
three compounds, respectively (Fig. S2C).  
 
Finally, we performed unsupervised hierarchical clustering of the sDSS per culture, to decipher 
subtype-selective drug sensitivities. Four distinct compound groups (1-4), as well as two major 
clusters exhibiting high or low sensitivity profiles, were identified (Fig. 2B). Of the 61 compounds 
on July 29, 2019. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1535-7163.MCT-18-0573 
 13 
tested, only daporinad, an inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase), and 
the FDA-approved NSCLC agent gemcitabine, showed sensitivity in all culture subtypes (Group 
3). Furthermore, all cultures showed resistance (sDSS < -5) to EGFR inhibitors (Group 4), in 
agreement with the known absence of clinical response of KRAS mutant NSCLC to EGFR 
inhibition (25). Consistent with their higher proliferation rate, KL;ASC cultures showed increased 
sensitivity to cytotoxic and antimitotic agents (Fig. 2C; Group 1). Drug sensitivity comparisons 
revealed subtype-selective hits (Fig. 2C): in addition to compounds targeting proliferation, 
topoisomerase, BET, and HDAC inhibitors were also selectively effective against KL;ASC 
cultures (Group 2). In addition,  in line with published data, KL cultures of both histotypes 
showed increased sensitivity to HSP90 inhibitors compared to KP cells (26). Overall, we conclude 
that, in spite of a detected heterogeneity in drug response among cultures of the same subtype, 
drug profiling identifies tumor histotype and genotype as important determinants of response, 
suggesting that the taken approach can identify subtype-selective vulnerabilities.  
 
Short-term MEK inhibition in vitro leads to adaptive PI3K/AKT activation in all culture 
subtypes 
Interestingly, despite the expression of oncogenic KRAS in all cultures, only KL;AC cultures 
exhibited greater sensitivity to the MEK inhibitors trametinib or selumetinib compared to NL 
cultures (Fig. 2C). Consistent with the DSRT results, KL;AC cultures also showed higher 
response to a dose series of trametinib treatment (0.5 – 500 nM) compared to other culture 
subtypes (Fig. 3A). Next, to decipher how signaling following MEK inhibition relates to response, 
we evaluated the effect of MEK inhibition on MAPK and PI3K/AKT pathway activities. Cells 
were either treated with a titrated amount of trametinib (5-50 nM) for 48 h, or with 50 nM 
trametinib for different time points (4-72 h). Treatment with 50 nM trametinib strongly inhibited 
MAPK signaling in all culture subtypes, evidenced by loss of ERK phosphorylation (Fig. 3B-C, 
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S3A-B). However, induction of AKT phosphorylation was observed, suggesting adaptive 
activation of PI3K/AKT signaling to counter MAPK inhibition (Fig. 3B-C, S3A-B). Taken 
together, while acute response to MEK inhibition ex vivo was KL;AC-selective, all culture 
subtypes elicited adaptive signaling following MEK inhibition, leading to adaptive PI3K/AKT 
activation. 
 
Blockade of MEK in combination with RTKs identifies NSCLC subtype-selective effective 
drug combinations  
Studies using KRAS mutant cells have reported the adaptive activation of RTKs viz. ERBBs, 
FGFR, IGFR1, AXL and MET upon MAPK pathway inhibition (25,27-30). To explore the 
possible involvement of RTKs in the activation PI3K/AKT signaling, we treated cultures with 
dose series of pan-ERBB, FGFR, IGF1R, AXL and MET inhibitors, either as single agents or in 
combination with trametinib. DSSs were analyzed to identify synergistic interactions indicative of 
RTK-driven adaptive resistance to MEK inhibitor. This showed selective high sensitivity of both 
KL histopathology type cultures to combinatorial treatment with trametinib and the pan-ERBB 
inhibitor afatinib (Fig. 4A-B and Fig. S4A), yet all other tested treatments were ineffective in 
these short-term 72 h assays (Fig. S4B). Notably, absence of response was also seen following 
combination treatment with trametinib plus the FGFR inhibitor ponatinib, which contrasts with a 
reported efficacy against Kras mutant AC tumors in the KP model (30). We therefore extended the 
approach by performing clonogenicity assays to assess long-term 11 day treatment effects. 
Interestingly, this showed that long-term treatment with single agent afatinib selectively reduced 
the clonogenic potential of both KL cultures, an effect that was further exacerbated by combining 
afatinib with trametinib (Fig. 4C-D). Furthermore, combinatorial trametinib plus ponatinib 
treatment selectively suppressed the growth of AC histotype cultures of both genotypes (Fig 4C-
D). Taken together, analysis of short- and long-term treatment responses revealed KL culture-
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selective sensitivity to ERBB network inhibition, particularly in combination with MEK 
inhibition, as well as AC culture subtype-selective sensitivity to combinatorial MEK plus FGFR 
inhibition.  
 
The detected culture subtype-selective differences in drug sensitivity prompted us to measure the 
phosphorylation of ERBB family RTKs and the FGFR adaptor FRS2, to indicate RTK activation 
before and after MEK inhibition in the three culture subtypes. Although slight differences between 
biological replicates were detected, clear trends towards culture subtype-selective responses were 
seen: while KL;ASCs and KL;ACs both activated ERBB family RTKs following MEK inhibition, 
this was evidenced as sustained ERBB3 and increased EGFR phosphorylation in KL;ASCs, while 
KL;ACs showed increased EGFR and ERBB2 phosphorylation (Fig. 4E-F and S4C-D). In 
contrast, KP;AC cultures lacked ERBB phosphorylation yet showed sustained FRS2 
phosphorylation following trametinib treatment (Fig. 4E-F and S4C-D), and increased FRS2 
phosphorylation was similarly detected in KL;AC cultures (Fig. 4E-F and S4C-D). Furthermore, 
in agreement with the detected absence of short-term response to single agent afatinib treatment, 
immunoblot analysis showed that while afatinib treatment effectively blocked EGFR activity in all 
three cultures, it did not inhibit ERK or AKT phosphorylation during a 72 h time course (Fig. 4G 
and S4E). Taken together, biochemical dissection showed KL-selective adaptive ERBB activation, 
albeit by somewhat different mechanisms in the two histopathology subtypes, and AC-selective 
adaptive FGFR activation following MEK inhibition, and that the co-inhibition of such adaptive 
signals together with MEK conferred loss of clonogenicity.   
   
Finally, we asked whether inhibition of adaptive or sustained ERBB signaling, and consequent 
inhibition of downstream PI3K/AKT survival signaling, resulted in culture subtype-selective cell 
death following MEK and pan-ERBB inhibition. As expected, 48 h treatment with trametinib 
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reduced pERK, while afatinib reduced the levels of pERK and pERBBs. However, only 
combination treatment resulted in increased cleaved caspase-3 expression specifically in the 
KL;ASC and KL;AC, but not the KP;AC cultures (Fig. 4H). Collectively, these results argue that 
NSCLC subtype-selective RTK activation counters MEK inhibition: while KL cultures of both 
histopathology types exhibit intrinsic or adaptive ERBB family RTK activation, AC cultures of 
both genotypes employ adaptive FGFR activation following MAPK inhibition. 
 
ERBB inhibition impairs growth of KL but not KP NSCLC tumors  
To investigate how the identified in vitro sensitivity to single or combinatorial drug treatment 
reflects on in vivo drug sensitivity, we initially designed a four week treatment experiment, with 
vehicle, trametinib, afatinib, or their combination in KL and KP mice. However, toxicity 
symptoms including a rapid reduction in body weight were observed already following two weeks 
of combination drug treatment (daily for five consecutive days; two days off treatment), 
specifically in tumor-bearing KL and KP mice (Table S2). We therefore adjusted the dosing to 
three times per week for four weeks, and assessed treatment outcome by tumor burden analysis. 
This showed that single agent afatinib or trametinib treatment was sufficient to reduce the tumor 
burden in KL and KP mice, respectively, and that the addition of trametinib did not provide an 
additional anti-tumor effect (Fig. 5A-B). Together, these results suggest a NSCLC subtype-
selective sensitivity to RTK inhibition, and show that both AC and ASC histopathology subtype 
KL tumors exhibit sensitivity to pan-ERBB inhibition in vivo. 
  
In situ NSCLCs show subtype-selective ERBB activity markers   
Next, we set out to investigate how the detected KL tumor-selective sensitivities to pan-ERBB 
inhibition correlate with baseline ERBB network biomarkers expressed in in situ tumors, and first 
measured the baseline phosphorylation of ERBB family RTKs Interestingly, all ERBB receptors 
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were predominantly phosphorylated in the SCC subregions of ASC tumors, while the AC regions, 
as well as KL;AC and KP;AC tumors, showed variable yet significantly low ERBB 
phosphorylation (Fig. 6A-B). We next asked if SCC histotype-specific ERBB phosphorylation 
was representative of human NSCLCs, and analyzed a tissue microarray encompassing ASCs (13 
samples), ACs (25 samples), and SCCs (28 samples) (Fig. 6C and S5). Replicate cores taken from 
separate regions of identical sample blocks showed subtle variation in pERBB expression, 
suggesting some spatial differences in ERBB receptor activation (Fig. 6C). Interestingly, similar 
to the murine data, baseline EGFR phosphorylation was detected more often in SCC tumors 
(11/28) than in AC tumors (3/25), Fisher’s test p=0.031, and ERBB3 phosphorylation was 
detected more often in ASC (4/13) or SCC (6/28) tumors than in AC tumors (0/25) (Fisher’s test 
p=0.009 for ASC compared to AC;  p=0.024 for SCC compared to AC) (Fig. 5C-D). Together, 
these results indicate spatial heterogeneity in ERBB family receptor activation, showing high 
levels of baseline EGFR and ERBB3 phosphorylation in both human and murine SCC, but not 
AC, histopathology tumors.  
 
Finally, we asked how the KL tumor-selective in vivo response to long-term ERBB inhibition with 
afatinib related to the differential expression of ERBB-activating ligands, and compared the 
expression of a set of ERBB ligands (Epgn, Tgfa, Nrg1, Areg and Ereg) between normal lung and 
tumor tissues using RT-qPCR. This showed significant expression of all tested ligands in 
KL;ASCs, and high expression of Tgfa, Areg, and Ereg in KL;ACs. Conversely, only Areg was 
found expressed in KP;ACs compared to normal tissue, albeit at lower levels than in KL tumors 
(Fig. 6D). Thus, we found that the in vivo sensitivity to pan-ERBB inhibition selectively in KL 
tumors correlated with high levels of ERBB ligand expression and predominant ERBB receptor 
activity in in situ tumors.   
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DISCUSSION 
 
Until now, panels of commercially available NSCLC cell lines have mostly been used to 
understand the relationship between genotypes and drug response (31,32). However, in the era of 
precision medicine, patient-derived primary tumor cell cultures are increasingly used to identify 
patient-selective drug sensitivities. Prior to implementation of this strategy in clinical routines, 
GEM models provide an attractive means to test the ability of primary cultures to identify drug 
sensitivities predictive of in vivo responses. Traditionally, the immortalization of murine primary  
cultures requires p53 inactivation (33,34), prohibiting the investigation of drug responses in the 
context of wildtype p53. Here we show that long-term KL cultures can readily be established 
using the CR methodology, permitting dissection of LKB1 function independently of p53 loss, 
and that CR cultures retain the genotypes and growth properties of the native tumors. Analysis of 
histotype-specific lineage markers showed that while ASC cultures retained p63 and NKX2-1, AC 
cultures lost NKX2-1 expression, suggesting their dedifferentiation, a known feature of the CR 
method (35). Comparative gene expression analyses similarly demonstrated an AC 
histopathology-selective lack of cell line signature clustering with fresh tumors (36). Together, 
this suggests that AC cultures show increased molecular divergence compared with their native 
tumors, highlighting that the coupling of in vitro drug sensitivities with in vivo validation is 
fundamental to assess the predictive power of primary cultures.  
 
By utilizing in vitro and in vivo models of Kras mutant NSCLC, previous studies have reported 
that adaptive activation of ERBBs or FGFR RTKs can confer resistance to MEK inhibition 
(29,30,37). We extend these findings, and show that Kras mutant NSCLCs stratify according to 
subtype-selective intrinsic or adaptive RTK activation following MEK inhibition: activation of 
ERBBs in KL cultures, and FGFR activation in AC cultures. Although slight differences were 
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observed between biological replicate cultures of the two KL histopathology subtypes, sustained 
ERBB3 activation was consistently detected in ASC cultures as opposed to adaptive ERBB2 
activation in AC cultures, suggesting histopathology subtype-selective ERBB network activities. 
Importantly, we demonstrate that the above underpins KL genotype-selective sensitivity to ERBB 
plus MAPK inhibition, and AC histotype-selective sensitivity to FGFR plus MAPK pathway 
inhibition (Fig. 6E). Our finding that KP;AC cultures exhibit sensitivity to combinatorial MEK 
plus FGFR inhibition corroborates data from Manchado and colleagues, who demonstrated tumor 
regression following trametinib plus ponatinib combination treatment in the KP GEMM (30). We 
broaden this to the KL model by showing that KL;ACs also respond to this drug combination, 
implying AC histotype- rather than KP genotype-selective sensitivity. Together, these results 
highlight the ability of primary cultures to expose intrinsic and adaptive RTK signaling networks 
and associated therapeutic responses. 
 
Prior to application of primary cultures in clinical settings, it is important to evaluate the ability of 
such cultures to model in vivo drug responses. In a four week tumor burden study, single agent 
afatinib treatment was sufficient to reduce the tumor burden in the KL GEMM, making the effect 
of additional trametinib treatment difficult to evaluate. Yet, single agent afatinib sensitivity was 
also evident in long-term in vitro colony formation assays, in principle validating the capacity of 
cultures to model in vivo sensitivity. On the contrary, tumors in the KP GEMM showed sensitivity 
to single agent trametinib treatment, which is in agreement with a previous report (30), yet differs 
from the detected absence of single agent trametinib response in KP;AC cultures. This suggests a 
greater ability of KP;AC cultures to induce resistance against MEK inhibitors in vitro, possibly 
explained by deregulated cell cycle checkpoints or altered metabolic reprogramming (38). 
Importantly, KL selective-sensitivity to pan-ERBB inhibition was exacerbated by MEK inhibition 
in cultured cells, correlating with increased adaptive activation of the ERBB RTK network 
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following MEK inhibition. While it remains to be evaluated whether long-term afatinib treatment 
eventually leads to tumor resistance, and if this can be reversed by combinatorial trametinib 
treatment, the finding that response to pan-ERBB inhibition is detected in tumors with high 
baseline ERBB phosphorylation and autocrine/paracrine acting ligands suggests that these can 
serve as biomarkers of in vivo response. 
 
Using Kras-driven tumor models, two elegant recent studies showed that ERBBs mediate lung 
tumorigenesis through feed-forward signaling mechanisms, demonstrating impressive long-term 
anti-tumorigenic effects of pan-ERBB inhibitor alone or together with MEK inhibitor (39,40). 
These complement our finding of pan-ERBB inhibitor response in the KL model, and we provide 
novel evidence that response is also seen in adenosquamous histopathology subtype tumors. 
Importantly, our finding that pan-ERBB inhibition does not control KP tumors indicates that Kras-
driven NSCLCs stratify based on usage of the ERBB network, underpinning sensitivity to pan-
ERBB inhibition. Interestingly, a clinical trial investigating combinatorial selumetinib (a MEK 
inhibitor) plus afatinib treatment in KRAS mutant NSCLC patients is ongoing (NCT02450656) 
(41), which given the high frequency of KRAS mutations in ACs, is likely to predominantly 
analyze AC subtype tumors. Our results however rather suggest a need to perform a clinical trial 
in patients further stratified according to ERBB network biomarker expression, histopathology, 
and co-occurring genetic alterations, with TP53 mutation as a possible exclusion marker. 
 
Taken together, our study contributes original knowledge that helps to understand how we can 
stratify Kras mutant NSCLCs into distinct subgroups based tumor subtype-selective RTK 
signaling networks, particularly those involving ERBB and FGF RTKs. Furthermore, our proof-
of-concept study demonstrates the utility of NSCLC-derived primary cultures as a diagnostic 
model for pharmacological exploration. We conclude that in addition to genetic profiling-based 
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targeted therapies, also the application of in vitro drug testing coupled with the analysis of tissue 
biomarkers of response has a capacity to expose tumor samples likely to exhibit drug response in 
clinical settings. 
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FIGURE LEGENDS 
 
 
Figure 1. Establishment and characterization of pathology-specific conditionally 
reprogrammed murine NSCLC cultures. (A) Representative phase-contrast images depicting 
KL;ASC, KL;AC, and KP;AC tumor-derived epithelial cells, cultured either as CRCs or as 
conventional cultures in RPMI medium at passage 2 or 3. The red dotted line separates epithelial 
cells from the surrounding feeder cells. Data shows that CR culture is required for the growth of 
KL tumor-derived cells. Scale bar 200 m. (B) Western blot analysis of KL;ASC, and KL;AC 
source tumor references (T) and matched CRCs (C) at passage 6, probed with the indicated 
antibodies (C) Western blot analysis of KP;AC source tumor references (T) and matched CRCs 
(C) at passage 6, probed with the indicated antibodies, depicting E-cadherin, vimentin, LKB1, and 
β-actin expression. In (B) and (C), the C1, and C2 cultures of all the subtypes were established 
without EpCAM purification. IR indicates γ-irradiated cells. (D) Representative images of 
colony formation assays for KL;ASC (n=3), KL;AC (n=3), KP;AC (n=4), and NL (n=3) CRCs at 
passage 7, in the presence or absence Y-27632. (E) Quantification of colony formation assays 
depicted in (D). Error bars represent ± SEM. Two-tailed unpaired Student’s t-test p values are 
*p<0.05, **p<0.01, ***p<0.001. 
 
Figure 2.  Drug sensitivity and resistance testing identifies histotype-selective vulnerabilities. 
(A) Schematic outline of the drug screening strategy on murine NSCLC or NL CRCs. (B) 
Heatmap representing the combined results of phase-I and phase-II screen, showing sDSS profiles 
of compound-treated KL;ASC (n=5), KL;AC (n=4), and KP;AC (n=8) cultures (total of 61 
compounds). Cultures included in the Heatmap are established from individual tumors and marked 
with a unique culture ID. Red colors indicate increased sDSS (lower cell viability), while blue 
colors indicate decreased sDSS (higher cell viability). Drug responses were clustered by using a 
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complete linkage method, coupled with Euclidian distance measurement. Four distinct groups 
with unique drug response patterns were identified. (C) Average sDSS values showing responses 
of compounds for each culture subtype. Each dot represents an individual cell line, and data labels 
indicate the number of compounds of each category used for analysis. Data is represented as 
means ± SEM. Two-tailed unpaired Student’s t-test p values are *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3. MEK inhibition leads to KL;AC-selective reduction in viability and instigates 
adaptive AKT phosphorylation. (A) Dose-response curves following trametinib (TR) dose series 
treatment in KL;ASC (n=4), KL;AC (n=4) and KP;AC (n=4) cultures. (B) Immunoblot of 
KL;ASC, KL;AC and KP;AC cultures treated with vehicle (C; DMSO) and various concentration 
of TR (5, 10, 25 and 50 nM) for 48 h, or (C) treated with 50 nM TR for various time points (4, 24, 
48 and 72 h), and probed with indicated antibodies. Two-tailed unpaired Student’s t-test *p<0.05, 
**p<0.01, ***p<0.001. 
 
Figure 4. Combinatorial inhibition of MEK and subtype-selective RTKs suppresses adaptive 
resistance mechanisms. (A) Heatmap representing the drug sensitivity profiling of indicated 
single agents and drug combinations in KL;ASC (n=3), KL;AC (n=3) and KP;AC (n=3) cultures. 
Single agents were tested with nine doses (0.5 nM – 500 nM for trametinib; 10 nM – 1000 nM for 
all other drugs). For combination screens, 5 nM of trametinib was used in addition to eight 
different doses of the RTK inhibitor viz. afatinib (AF; pan-ERBB inhibitor), ponatinib (PO; FGFR 
inhibitor), linsitinib (LI; IGF1R inhibitor), BGB324 (BG; AXL inhibitor) and capamatinib (CA; 
MET inhibitor). (B) DSS for trametinib, afatinib, and combination treatment of KL;ASC (n=4), 
KL;AC (n=4) and KP;AC (n=4) cultures. (C) Representative images from clonogenicity assays of 
KP;AC, KL;AC and KL;ASC cells treated for 11 days with trametinib (5 nM), afatinib (250 nM), 
ponatinib (250 nM), or the indicated combinations. (D) Relative colony area calculated using the 
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‘Colony area’ imageJ plugin. Bar graph represents relative colony areas normalized to vehicle 
controls. (E) Immunoblot analysis of various KL;ASC, KL;AC and KP;AC cultures treated with 
vehicle (C; DMSO) or with 50 nM of trametinib for various time points (4, 24, 48 and 72 h), or 
(F) with different concentrations of trametinib (5, 10, 25 and 50 nM) for 48 h cells, and probed 
with the indicated antibodies. (G) Immunoblots of KL;ASC, KL;AC and KP;AC cultures treated 
with vehicle (C; DMSO) or with 1000 nM afatinib for various time points (4, 24, 48 and 72 h), 
and probed with indicated antibodies. (H) Immunoblots of KL;ASC and KL;AC cultures treated 
for 48 h with vehicle (C), 50 nM trametinib, 1000 nM afatinib, or their combination, and probed 
with indicated antibodies. Data is represented as means ± SEM. Student’s t test p values are 
*<0.05, **p<0.01, ***p<0.001. 
 
Figure 5. Tumor genotype-selective sensitivity to MEK or ERBB pathway inhibition. (A) 
Representative H&E images of lung sections from KL or KP mice treated for four weeks with 
vehicle, TR, AF, or their combination. The data show that single agent AF and its combination 
with TR reduces KL tumor burden, and single agent TR and its combination with AF reduces KP 
tumor burden; n=3-4 mice for each group. Scale bar 5 mm. (B) Quantification of the data shown 
in (A). Each dot represents an individual mouse. Error bars represent ± SEM. Two-tailed unpaired 
Student’s t-test values are *p<0.05, **p<0.01, ***p<0.001.  
 
Figure 6.  Murine and human NSCLCs show tumor subtype-selective spatial heterogeneity 
in ERBB network activity. (A) Representative IHC images of pEGFR, pERBB2, pERBB3 in 
KL;ASC (n=4 mice), KL;AC (n=3-6 mice), and KP;AC (n=7-8 mice) tumors, showing significant 
activation of ERBB receptors in the SCC regions of  ASC tumors. Orange dotted lines in ASC 
tumors separate the AC from the SCC regions. Arrows indicate areas shown in the higher 
magnification insets; insets with black or orange borders show the SCC or AC regions of ASCs, 
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respectively. Scale bars are 2 mm or 50 m for high or low magnifications, respectively. (B) 
Quantification of the IHC analyses shown in (A). For statistical analyses, the average per mouse 
was used as experimental units. Error bars represent ± SEM. Kolmogorov–Smirnov test p values 
are *p<0.05, **p<0.01, ***p<0.001. (C) Schematic representation of IHC analyses of pEGFR, 
pERBB2, and pERBB3 expression in human NSCLC TMAs. Red or white bars indicate presence 
or absence of expression of the indicated markers, respectively. Replicate samples taken from 
different subregions of the same tumor are indicated by a dividing line in the bar. (D) RT-qPCR 
analysis of ERBB ligands Epgn, Tgfa, Nrg1, Areg, and Ereg in normal lung (n=4), KL;ASC 
(n=11), KL;AC (n=8), and KP;AC (n=8) tissue samples. Error bars represent ± SEM. Two-tailed 
unpaired Student’s t-test *p<0.05, **p<0.01, ***p<0.001. (E) Schematic depicting Kras mutant 
NSCLC subtype-selective drug sensitivities informed by intrinsic and adaptive usage of distinct 
ERBB- or FGFR-driven signaling networks. Resistance to MEK inhibition is driven by baseline as 
well as feedback activation of ERBBs or FGFR in KL or AC subtypes, respectively. Purple lines 
indicate feedback activation of RTKs following MEK inhibition. The KL genotype-selective 
sensitivity to pan-ERBB inhibition as well as MEK plus pan-ERBB inhibition correlates with 
predominant expression of ERBB ligands and phosphorylation of ERBB RTKs in KL tumors. 
Drug or drug combinations validated in Kras-driven GEMMs are indicated by asterisks; their 
black or red color indicates results from this study or Manchado et al  (30), respectively. 
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